Abstract
This article provides background information regarding the secondary source pharmaceutical wholesaling market, how it operates, and how some of its operators introduce counterfeit, adulterated, mislabeled, stolen, or other undesirable drugs into the nation's drug supply. After this discussion, the article details investigative techniques that can be used to detect bad wholesaling practices. Finally, the article ends with a series of recommendations specifically targeted to regulators and industry actors intended to curb the activities of bad wholesalers.
Keywords
Get full access to this article
View all access options for this article.